Evolution potentielle d'adocia sans prendre en compte l'arbitragUne rapide analyse en cours d'Adocia, sans prendre en compte le résultat potentiel du désaccord avec Eli Lilly. Je ne prends en compte uniquement l'analyse graphique.
2.37 MUSD
11.13 M
About ADOCIA
Sector
CEO
Olivier Soula
Headquarters
Lyon
Website
Employees (FY)
80
Founded
2006
FIGI
BBG006JP2X69
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: Biochaperone Lispro, Combo, M1pram, Glucagon, Gla Glp-1, Glucagon Glp-1 & Cell Therapy. The company was founded by Gérard Soula, Olivier Soula and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
